No Impact of Prophylactic Corticosteroid Use in Patients Receiving Axicabtagene Ciloleucel for Large B-Cell Lymphoma

被引：0
|
作者：
Melody, Megan [1 ,2 ]
Franco, Stephanie [3 ]
Odetola, Oluwatobi [1 ,2 ]
Lin, Adam [1 ,2 ]
Moreira, Jonathan [1 ,2 ]
Carson, Kenneth [1 ,2 ]
Ma, Shuo [1 ,2 ]
Winter, Jane N. [1 ,2 ]
Gordon, Leo [1 ,2 ]
Karmali, Reem [1 ,2 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL USA
[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[3] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
CT; LBCL; CAR T-cell therapy; CRS; ICANS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT-630
引用
收藏
页码：S611 / S612
页数：2
相关论文
共 50 条
  • [41] Cladribine and Cyclophosphamide Lymphodepletion Prior to Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma
    Ionescu, Filip
    Shah, Bijal D.
    Menges, Meghan
    Reid, Kayla
    Bailey, Hanna
    DiMaggio, Elizabeth
    Gonzalez, Rebecca
    Bachmeier, Christina A.
    Corallo, Salvatore
    Delgado, Luis Cuadrado
    Mohammed, Turab
    Nishihori, Taiga
    Khimani, Farhad
    Lazaryan, Aleksandr
    Liu, Hien
    Davila, Marco
    Perna, Fabiana
    Chavez, Julio C.
    Locke, Frederick L.
    Jain, Michael D.
    BLOOD, 2023, 142
  • [42] Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
    Baird, John H.
    Epstein, David J.
    Tamaresis, John S.
    Ehlinger, Zachary
    Spiegel, Jay Y.
    Craig, Juliana
    Claire, Gursharan K.
    Frank, Matthew J.
    Muffly, Lori
    Shiraz, Parveen
    Meyer, Everett
    Arai, Sally
    Brown, Janice
    Johnston, Laura
    Lowsky, Robert
    Negrin, Robert S.
    Rezvani, Andrew R.
    Weng, Wen-Kai
    Latchford, Theresa
    Sahaf, Bita
    Mackall, Crystal L.
    Miklos, David B.
    Sidana, Surbhi
    BLOOD ADVANCES, 2021, 5 (01) : 143 - 155
  • [43] Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population
    Lauren C. Shapiro
    Jennat Mustafa
    Amanda Lombardo
    Fariha Khatun
    Felisha Joseph
    Kailyn Gillick
    Anjali Naik
    Richard Elkind
    Michelly Abreu
    Karen Fehn
    Alyssa de Castro
    Kith Pradhan
    Donika Binakaj
    Randin Nelson
    Monika Paroder
    Joan Uehlinger
    Kira Gritsman
    R. Alejandro Sica
    Noah Kornblum
    Aditi Shastri
    Ioannis Mantzaris
    Lizamarie Bachier-Rodriguez
    Amit Verma
    Ira Braunschweig
    Mendel Goldfinger
    Bone Marrow Transplantation, 2021, 56 : 1761 - 1763
  • [44] Original Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma
    van Meerten, Tom
    Kuruvilla, John
    Song, Kevin W.
    Thieblemont, Catherine
    Minnema, Monique C.
    Forcade, Edouard
    De Guibert, Sophie
    Kersten, Marie Jose
    Mutsaers, Pim G. N. J.
    Wermke, Martin
    Zheng, Yan
    Xue, Allen
    Winters, Joshua N.
    Nater, Jenny
    Shen, Rhine R.
    Spooner, Clare
    Neumann, Frank
    Kim, Jenny J.
    Topp, Max S.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (06):
  • [45] Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma
    Halford, Zachery
    Anderson, Mary Kate
    Bennett, Lunawati L.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (03) : 390 - 405
  • [46] A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma
    Looka, Andrew
    Qualls, David A.
    Matthews, Daniel
    Redd, Robert A.
    Sakellis, Christopher
    Duffy, Caitlyn
    Dela Cruz, Jamie
    Saucier, Anna
    Armand, Philippe
    Crombie, Jennifer L.
    Fisher, David C.
    Jacobsen, Eric D.
    Kim, Austin I.
    Lacasce, Ann S.
    Merryman, Reid W.
    Parry, Erin M.
    Jacobson, Caron A.
    BLOOD ADVANCES, 2025, 9 (03) : 455 - 462
  • [47] Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
    Neelapu, Sattva S.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Deol, Abhinav
    Miklos, David B.
    Bartlett, Nancy L.
    Braunschweig, Ira
    Jiang, Yizhou
    Kim, Jenny J.
    Zheng, Lianqing
    Rossi, John M.
    Locke, Frederick L.
    BLOOD, 2020, 135 (23) : 2106 - 2109
  • [48] Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma in the United States
    Roth, Joshua
    Sullivan, Sean D.
    Lin, Vincent W.
    Purdum, Anna
    Navale, Lynn
    Cheng, Paul
    Ramsey, Scott D.
    BONE MARROW TRANSPLANTATION, 2018, 53 : 874 - 875
  • [49] Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas
    Riedell, Peter A.
    Bishop, Michael R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [50] Real World of Experience Axicabtagene Ciloleucel for The Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Spain
    Kwon, Mi
    Bailen, Rebeca
    Lopez Corral, Lucia
    Luis Reguera, Juan
    Iacoboni, Gloria
    Hernani Morales, Rafael
    Ortiz Maldonado, Valentin
    Bastos Oreiro, Mariana
    Martin Garcia, Alejandro
    Martinez Cibrian, Nuria
    Barba, Pere
    Delgado, Julio
    Jose Terol, Maria
    Diez Martin, Jose Luis
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 37 - 39
12345